A recent study published in the journal Molecular Cancer Therapeutics by researchers at University College Davis Comprehensive Cancer Center in the US, shows that docosahexaenoic acid (DHA), a fatty acid commonly found in fish and fish oil supplements, reduces the invasiveness of renal cell carcinomas (RCC), growth rate, and blood vessel growth when combined with the anti-cancer therapy regorafenib.
Regorafenib is one of a new generation of anti-cancer therapies that attack tyrosine kinases – enzymes that activate other proteins. Unfortunately, kidney cancers mutate to resist these therapies.
Although the results from this study are encouraging, the researchers caution that these benefits are quite narrow, relying on the synergistic interaction between regorafenib and DHA. In other words, there’s no proof that taking fish oil supplements or eating fish like salmon would have any impact against kidney cancer on their own.